Nav: Home

Prescription costs increase for low-value treatments despite reduction in numbers

May 22, 2018

Despite a fall in prescription numbers for low-value treatments, the overall cost of prescribing these items in English primary care has risen, according to new research published by the Journal of the Royal Society of Medicine. NHS England has identified low-value treatments deemed to be ineffective, over-priced and of low clinical value, in order to increase value from the £17.4bn NHS medicines bill. The researchers found a strong association between practices with a higher proportion of patients over 65 and low-value prescribing. They also found prescribing behaviour clustered by Clinical Commissioning Group (CCG), the NHS bodies responsible for planning and commissioning health care services in their local area.

The researchers, from the Nuffield Department of Primary Care Health Sciences, University of Oxford, assessed the current use of low-priority treatments identified by NHS England, their change in use over time and the extent and reasons for variation in prescribing.

In addition to the national results presented in the paper, the researchers also shared all data on prescribing at all individual NHS practices. This is published through an interactive website, OpenPrescribing.net, which can be used by GPs, local commissioners, and even patients, to see where there are possible savings opportunities for individual prescribers.

Lead researcher Dr Ben Goldacre said: "There were almost one million fewer prescriptions for low-value items between July 2016 and June 2017, compared with the previous year. Despite the consistent downward trend in items, costs have risen, increasing by £4.5m when comparing 2016/17 with 2015/16.

The researchers found that while the cost per item has remained stable for most low-value treatments, for three items identified by NHS England, liothyronine (for hypothyroidism), trimipramine (an antidepressant) and co-proxamol (a painkiller), the cost has risen dramatically, by £73, £168 and £71 per prescription, respectively.

Dr Goldacre said: "Co-proxamol, liothyronine and trimipramine illustrate a concerning phenomenon, where despite successful efforts to limit prescribing numbers, costs have risen sharply." Giving co-proxamol as an example Dr Goldacre explained: "It's expensive because it was removed from the drug tariff, meaning that any prescriptions for it have to be sourced as a 'special' order. There is limited regulation of the cost of such special orders, making real world cost savings on such drugs difficult until there are a very small number of total prescriptions."

The researchers found that the strongest association with the level of prescribing cost at practice level was with the proportion of patients over 65, although they noted that this is perhaps not surprising given that older patients are generally more likely to receive prescriptions.

Commenting on the large degree in variation according to CCG, Dr Goldacre said: "This is likely to be due to differences in policy between different CCGs and practices, rather than clinical need."
-end-
Notes to editors

Trends and variation in prescribing of low-priority treatments identified by NHS England: a cross-sectional study and interactive data tool in English primary care (DOI: 10.1177/0141076818769408) by Alex J Walker, Helen J Curtis, Seb Bacon, Richard Croker and Ben Goldacre, will be published by the Journal of the Royal Society of Medicine at 00:05 hrs (UK time) on Wednesday 23 May 2018.

The link for the full text version of the paper when published will be:

http://journals.sagepub.com/doi/full/10.1177/0141076818769408

For further information or a copy of the paper please contact:

Rosalind Dewar
Media Office, Royal Society of Medicine
DL: +44-0-1580-764713
M: +44-0-7785-182732
E: media@rsm.ac.uk

The Journal of the Royal Society of Medicine (JRSM) is a leading voice in the UK and internationally for medicine and healthcare. Published continuously since 1809, JRSM features scholarly comment and clinical research. JRSM is editorially independent from the Royal Society of Medicine, and its editor is Dr Kamran Abbasi.

JRSM is a journal of the Royal Society of Medicine and it is published by Sage Publishing.

Sara Miller McCune founded SAGE Publishing in 1965 to support the dissemination of usable knowledge and educate a global community. SAGE is a leading international provider of innovative, high-quality content publishing more than 1000 journals and over 800 new books each year, spanning a wide range of subject areas. A growing selection of library products includes archives, data, case studies and video. SAGE remains majority owned by our founder and after her lifetime will become owned by a charitable trust that secures the company's continued independence. Principal offices are located in Los Angeles, London, New Delhi, Singapore, Washington DC and Melbourne. http://www.sagepublishing.com

SAGE

Related £ Articles:

Researchers create first-ever personalised sound projector with £10 webcam
A University of Sussex research team have demonstrated the first sound projector that can track a moving individual and deliver an acoustic message as they move, to a high-profile tech and media conference in LA.
Ash dieback is predicted to cost £15 billion in Britain
A team of researchers from the University of Oxford, Fera Science, Sylva Foundation and the Woodland Trust has calculated the true economic cost of ash dieback -- and the predictions, published today in Current Biology, are staggering.
People waste nearly a pound of food daily
Americans waste nearly a pound of food per person each day, but the exact amount of food we trash differs by how healthy your diet is, a new PLOS ONE study finds.
Every £1 spent on public health in UK saves average of £14
Every £1 spent on public health returns an extra £14 on the original investment, on average -- and in some cases, significantly more than that -- concludes a systematic review of the available evidence, published online in the Journal of Epidemiology & Community Health.
£4.5m 'Lab in a bubble' project could improve cancer care
A £4.5million University of Strathclyde project to produce bubble-sized 'laboratories' could boost cancer treatment, medical imaging and industrial processes.
More £ News and £ Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...